Manuscript (Research Article)

Long Title

Cooccurrence of N501Y, P681R and other key mutations in SARS-CoV-2 Spike

Short Title

Y501-R681 mutations in SARS-CoV-2 Spike

Authors

C. Lee,[1] S. Mangalaganesh,[2,3] L.O.W. Wilson,[1] M.J. Kuiper,[4] T.W. Drew,[2,5] S.S. Vasan[2,6]*

Affiliations

[1]Commonwealth Scientific and Industrial Research Organisation, Transformational Bioinformatics Group, North Ryde, NSW 2113, Australia
[2]Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Geelong, VIC 3220, Australia
[3]Monash University, Monash Biomedicine Discovery Institute, Clayton, VIC 3800, Australia
[4]Commonwealth Scientific and Industrial Research Organisation, Data61, Docklands, VIC 3008, Australia
[5]University of Nottingham, School of Veterinary Medicine and Science, Sutton Bonington Campus, LE12 5RD, United Kingdom
[6]University of York, Department of Health Sciences, York, YO10 5DD, United Kingdom
*Corresponding author. Email: vasan.vasan@csiro.au

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced five variants of concern (VOC) to date. The important Spike mutation 'N501Y' is common to Alpha, Beta, Gamma and Omicron VOC, while the 'P681R' is key to Delta's spread. We have analysed circa 4.2 million SARS-CoV-2 genome sequences from the world's largest repository 'Global Initiative on Sharing All Influenza Data (GISAID)' and demonstrated that these two mutations have cooccurred on the Spike 'D614G' mutation background at least 3,678 times from 17 October 2020 to 1 November 2021. In contrast, the Y501-H681 combination, which is common to Alpha and Omicron VOC, is present in circa 1.1 million entries. Two-thirds of the 3,678 cooccurrences were in France, Turkey or US (East Coast), and the rest across 57 other countries. 55.5% and 4.6% of the cooccurrences were Alpha's Q.4 and Gamma's P.1.8 sub-lineages acquiring the P681R; 10.7% and 3.8% were Delta's B.1.617.2 lineage and AY.33 sub-lineage acquiring the N501Y; the remaining 10.2% were in other variants. Despite the selective advantages individually conferred by N501Y and P681R, the Y501-R681 combination counterintuitively did not outcompete other variants in every instance we have examined. While this is a relief to worldwide public health efforts, *in vitro* and *in vivo* studies are urgently required in the absence of a strong *in silico* explanation for this phenomenon. This study demonstrates a pipeline to analyse combinations of key mutations from public domain information in a systematic manner and provide early warnings of spread.

Keywords: COVID-19, D614G, N501Y, P681R, SARS-CoV-2, Variants of Concern

1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the ongoing novel coronavirus disease 19 (COVID-19) pandemic, has a single-stranded positive-strand ribonucleic acid genome (ssRNA(+) genome) of size 26–32 kb, with high fidelity replication due to 3′-to-5′ exoribonuclease 'proof-reading' mechanism [P. Zhou 1, D.C. Bauer 2]. As this virus adapts to its human host, we have seen it evolve and present quasispecies diversity [D.C. Bauer 2, C.O. Wilke 3]. While most of the several thousands of mutations catalogued to date aren't substantial functional changes they have proven aetiologically useful [N.D. Grubaugh 4, E. Callaway 5].

Two years on since the start of the COVID-19 pandemic, we now have a good idea of the key mutations, especially in the Spike protein, which are punctuations in the evolutionary story of this virus to date. The D614G mutation reported in April 2020 resulted in the 'G-strain' with increased infectivity replacing the genomic background of this virus globally, although there was no impact on vaccine efficacy [E. Callaway 5, B. Korber 6, A.J. McAuley 7]. However, the N501Y mutation common to the Alpha, Beta, Gamma and Omicron variants of concern (VOC), has contributed to enhanced infection and transmission, reduced vaccine efficacy, and the ability of SARS-CoV-2 to infect new species such as wild type mice [Y. Liu 8, S.S. Abdool Karim 9, S. Riddell 10, M.J. Kuiper 11]. Another key mutation is the P681R which alters the furin cleavage site, and has been responsible for increased infectivity, transmission and global impact of the Delta variant [E. Callaway 12, Y. Liu 13, T.P. Peacock 14].

2. Methods

2.1 Study Objectives

Our primary objective is to investigate the risk of the three aforementioned 'mutations of current interest' (**MOCI**) cooccurring naturally due to convergent evolution and resulting in a SARS-CoV-2 variant that is of greater concern than those declared to date, noting that the latest Omicron VOC has the N501Y but not the P681R mutation. Our secondary objective is to demonstrate a methodology and pipeline to analyse the spread of variants containing combinations of important mutations. We have achieved this by mining data from GISAID, the Global Initiative on Sharing All Influenza Data, which is the largest and the most comprehensive repository of SARS-CoV-2 sequences [S. Elbe 15, D.C. Bauer 16]. We have used quasispecies theory and *in silico* modelling to interpret our findings to the extent possible, and recommended future research directions.

2.2 Bioinformatics Analysis

We mined GISAID data on 3 November 2021 containing 4,835,087 entries, 99.9% (4,831,865) sequenced from people who tested COVID-19 positive. Of these, 4,748,462 contained over 29 thousand nucleotides and were deemed 'complete'. GISAID has also defined a subset of these 4.8 million sequences, containing 3,519,085 entries, as 'high

coverage'. This is because 99% of their bases are defined; there is no unverified deletion or insertion; and unique mutations not seen in other sequences constitute fewer than 0.05% in these entries. Consequently, some of our analysis of the data downloaded on 1 November 2021 (4,766,139 sequences) required manual curation whenever we encountered incorrect dates, or low coverage sequencing that could skew our results. Supplementary **Table S1** provides GISAID's break down of these 4.8 million entries by variants containing the D614G (98.8%), N501Y (27.01%) and P681R (48.2%) mutations; by Alpha (23.9%), Beta (0.8%), Gamma (2.4%), Delta (47.8%), Omicron (0.0%) VOC; and by Lambda (0.2%) and Mu (0.3%) variants of interest (VOI).

Human-origin SARS-CoV-2 sequences over 29 kb length were aligned to the nominal reference (EPI_ISL_402123) using an in-house alignment pipeline that generated a file in the 'variant call format' (VCF) containing all the mutations as of 1 November 2021 [P. Zhou 1, D.C. Bauer 2]. In the VCF containing 4,294,469 genome sequences, we searched for entries with MOCI, for example, the Spike N501Y was searched at nucleotide position 23403 for an A to G transition. The EPI_ISL sample IDs containing our MOCI were merged with their respective GISAID metadata (location, date of collection, lineage) to create an annotated database. Supplementary **Table S1** shows the split up of these 4.3 million sequences by variants containing the D614G (98.8%), N501Y (29.2%) and P681R (44.2%) mutations; and by Alpha (26.3%), Beta (0.9%), Gamma (2.2%), Delta (43.8%), Omicron (0.0%), Lambda (0.2%) and Mu (0.3%) VOC/VOI.

Using a custom Python code, we identified the presence of the D614G, N501Y and P681R mutations, and combinations thereof (c.f. 'Data Availability' for our code). Our final dataset contained 4,177,098 entries after filtering out GISAID records with incomplete dates, i.e. retaining those with a 'YYYY-MM-DD' format. We ascertained whether these isolates are one of the VOC (and if yes, which sub-lineage), their location (country, state, and city depending on information available), and sample collection date. Using the latter, we calculated rolling averages over 14-days, as this window has been shown from previous experience to be an optimal period to reduce background noise, especially as the data is discrete and highly variable in size across countries [M.J. Kuiper 11]. However, unlike our previous study in which we were interested in macroscopic trends, here we have looked at every instance of key mutations cooccurring; therefore, we did not use a threshold or filter based on minimal sample size. Our analysis presents the spread of these mutations from the notional start of the SARS-CoV-2 pandemic (31 December 2019) to the end of our observation period (01 November 2021) with appropriate classifications (e.g. Alpha, Beta, Gamma, Delta).

2.3 Biomolecular Modelling

Fully glycosylated *in silico* models of the SARS-CoV-2 Spike protein were constructed based on the '6VSB' protein databank (PDB) structure [D. Wrapp 17], minus the transmembrane domain (residues 1161-1272) for additional computational efficiency as described previously [A.J. McAuley 7]. Models were simulated in aqueous solution (TIP3, water, 0.15M ions, NVT ensemble, 310K) using NAMD 2.14 software [J.C. Phillips 18]. Models were visualized with the visual molecular dynamics (VMD) program for large biomolecular systems which uses 3-D graphics and built-in scripting to assess the spatial arrangement of mutations and any complementary or inhibitory interactions [W. Humphrey 19].

3. Results: Frequency and Distribution of D614G, N501Y and P681R Mutations

The earliest record of these three MOCI coming together was in Slovenia on 17 October 2020, however, no further observations were recorded since then in that country. Mining of GISAID data found 3,678 entries (0.1%) containing the MOCI and a majority of these were in current VOC (Error! Reference source not found.) – Alpha (61.3%), Beta (0.4%), Gamma (6.4%), Delta (21.2%), Omicron (0.0%) – and a small proportion in current or former VOI – Mu (0.3%), Kappa (0.2%) and Iota (0.02%). A small proportion (10.2%) was also observed in other variants not classified as VOC, VOI, Variant Under Monitoring (VUM), or specific sub-lineages.

Figure 2 illustrates the MOCI frequency in countries with at least 50 recorded sequences – Brazil (5.8%), Denmark (1.9%), France (22.7%), Germany (3.6%), Sweden (5.2%), Turkey (21.4%), UK (3.6%) and USA (22.1%). These eight countries represent 86.4% of the cases containing the MOCI (**Figure 3A**, which shows a continuous timeline). Fifty-seven other countries recorded less than 50 entries for the period 17 October 2020 to 15 September 2021 (Supplementary **Table S2**).

Three countries – France, USA and Turkey – stand out as they each contribute to over 22% of the total instances of the MOCI cooccurring. It's unsurprising that these trends overlap with the spread of VOC in these nations (**Figures 3B-3D**), because there would have been more opportunities for Delta to acquire N501Y, and for Alpha or Gamma to acquire P681R (**Figures 3B-3F**). Such cooccurrences also appear to have happened over short periods of time, for instance during March to May 2021 in France and USA with the Alpha VOC; and between June and August 2021 in Turkey with the Delta VOC (**Figures 2 and 3B-3D**). This could be due to founder effects, but we cannot establish this by mining GISAID data alone; it will require detailed epidemiological investigations by national public health authorities, which is beyond the scope of this work. Nevertheless, from **Figure 2**, we can be reasonably sure that a number of independent events of convergent evolution (i.e. MOCI cooccurring) have taken place. It is worth investigating why we do not see as many instances of Delta acquiring N501Y in France and USA, even though they had a very high number of this VOC from July 2021.

4. Discussion

4.1 Y501-R681 almost always in the G614 background

From Supplementary **Table S3** we see that 3,688 entries contain N501Y+P681R, just ten more than the 3,678 entries that contain D614G+N501Y+P681R; in other words, the instances of N501Y cooccurring with P681R have almost always happened on the D614G background as predicted [E. Callaway 5, B. Korber 6, A.J. McAuley 7]. Although these three mutations are positioned sufficiently far apart in the 3-dimensional protein structure to suggest they don't interact (**Figure 4**), further studies are required to understand whether there may be indirect functional links that could enhance viral efficiency.

4.2 Predominance of Alpha Q.4 acquiring P681R and Delta acquiring N501Y

We see that the cooccurrence of the MOCI is largely due to; (a) the Alpha VOC acquiring the P681R (61.3%), and this has happened overwhelmingly in Alpha's Q.4 sub-lineage (89.9%) by definition; (b) the Delta VOC acquiring the N501Y (21.2%), and this has mainly happened in Delta's parent lineage (B.1.617.2; 50.6%) and also the sub-lineage AY.33 (17.9%); (c) the Gamma VOC acquiring the P681R (6.4%), predominantly in its P.1.8 sub-lineage (71.3%). It is worth noting that the Q.4 sub-lineage has the P681R by definition (https://outbreak.info/situation-reports?pango=Q.4). The Beta VOC acquiring the P681R only constituted 0.4% of the total occurrences, and this was almost entirely in the B.351.2 parent lineage (93.3%). Supplementary **Table S4** shows the results for other key Spike mutations in comparison to those obtained from GISAID. For H69del and Y145del, more samples were identified using our pipeline than on GISAID – 1,138,302 versus 1,123,439 before date filtering, and 2,563 versus 1,364 after date filtering.

4.3 Alpha acquiring P681R ahead of other VOC could be due to P/H681R

Alpha, Beta and Gamma each have N501Y, however Alpha was the first VOC to acquire P681R, both in terms of absolute (**Figure 3E**) and relative (**Figure 3F**) timelines, although Beta was reported four months before Alpha in May 2020. Alpha, especially its Q.4 sub-lineage, also contributes to most instances of the MOCI cooccurring. There is a possible biomolecular basis for this; P681H is present in Alpha, but not in the other two VOC. The Grantham scores associated with P681R (103) and P681H (77) are comparable and the H681R substitution is thus a conservative change (Grantham distance 29). There is only one way to get to Histidine (H) or Arginine (R) from Proline (P); and for H and R there is only one way to get to each other; and we see no structural reason from our *in silico* model as to why one should be preferred to the other. Thus, we could infer that some of the instances of Alpha acquiring P681R could have been due to a substitution of H with R, which is the signature of the Q.4 sub-lineage. Spike's 681st position is the fifth substrate sequence for cleavage recognition; both furin and the transmembrane serine protease 2 (TMPRSS2) cleave the Spike at 685/686 position with H (and possibly R) enhancing this process [A.J. McAuley 7, A.G. Remacle 20, M. Mahoney 21]. It is worth noting that to penetrate host cells, the SARS-CoV-2 Spike protein must be cut twice by host proteins. In the SARS-CoV-1 (SARS), both incisions occur after the virus has locked on to a cell. But with SARS-CoV-2, the presence of the furin cleavage site enables host enzymes like furin to make the first cut as newly formed viral particles emerge from an infected cell. These pre-activated viral particles can then go on to infect cells more efficiently compared to particles requiring two cuts. Thus, the P681R increases the susceptibility of the furin cleavage site in Delta VOC, and allows the exposure of the Spike's S2 subunit for better cell integration.

4.4 Cooccurrences have been reported predominantly in eight countries

Cooccurrences of the MOCI were observed with Alpha, Beta, Gamma and Delta VOC in 41, 8, 11 and 47 countries respectively, indicating convergent evolution, especially as much of the world was under lockdown during 2020-2021. Curiously, two thirds of the observations have been reported from just France, Turkey and USA; 86.3% from these three countries plus Brazil, Denmark, Sweden, UK and Germany (**Supplementary Table 2**). Several instances involve proximal regions, suggesting multiple founder effects (**Figures 2 and 5**). For example, in Denmark and Sweden, variants with the MOCI were concentrated in highly populous Hovedstaden and Svealand regions (Sörmland, Stockholm, Uppsala and Västmandland) [Statista website 22]; the MOCI frequencies were

also correlated with the most common lineage in respective countries and regions, suggesting community transmission, although these MOCI did not go on to become the dominant variant in those locations. This is in line with most within-host variants getting lost during transmission, and only a few founding infections being maintained in a given population [K.A. Lythgoe 23].

Cooccurrence of the MOCI in the UK occurred mostly with the Alpha VOC's B.1.1.7 and Q.4 from late 2020 to May 2021; followed by the second wave of the Delta VOC since April 2021, especially in AY.4 that had the highest (58%) prevalence (**Figure 2**). The former period had ten times the death rate (~1200 per week between September 2020 and March 2021) compared to the latter (~120 per week; probably due to lockdowns and 30% of the population already double-vaccinated). In the UK which has a very high rate of sequencing, the overall numbers of cooccurring MOCI were still low (133 records, 88% in England). Of these, there were respectively 52, 39 and 18 instances of the AY.4 acquiring N501Y, and the B.1.1.7 and Q.4 acquiring P681R [outbreak.info 24, Our World in Data 25]. It is possible that the lockdown protocols and vaccination coverage may have influenced the observed viral transmission dynamics [Institute for Government 26]. In the Americas, most of 1,078 cooccurrences of the MOCI were detected either in the US East Coast (673 entries), or in the Sul (Santa Catarina) and Sudeste (São Paulo, Rio de Janeiro) regions in the South and Southeast of Brazil (284 entries). These trends could be due to founder effects and lack of travel restrictions from early 2021, especially in the United States [Ballotpedia 27] (**Figure 2 and 5)**. In Brazil, the cooccurrences of the MOCI also corresponded with the prevalence of P.1 until August 2021 after which the AY.99.2 became the dominant variant (Supplementary **Figure S3**). Unfortunately, regional and city level information was not available for Turkey on GISAID, preventing further analysis and insights and highlighting the importance of metadata [D.C. Bauer 16].

4.5 Y501-R681 doesn't outcompete other variants

From our analysis, SARS-CoV-2 isolates containing Y501-R681 in Spike did not outcompete other variants in every single instance we have examined (**Figures 2 and 3)**, which is both counterintuitive and a relief to worldwide public health efforts. Although individually these two mutations have been reported to confer selective advantage [Y. Liu 8, S.S. Abdool Karim 9, S. Riddell 10, M.J. Kuiper 11, E. Callaway 12, Y. Liu 13, T.P. Peacock 14], their combination apparently has not and we have not found any compelling biomolecular reason for this (**Figure 4**). It would be desirable to conduct *in vitro* and *in vivo* studies to gain a better understanding, either using infectious clones and reverse genetics [T.T.N. Thao 28, X. Xie 29, Y.J. Hou 30, X. Xie 31], or using naturally occurring comparable isolates with and without these mutations [see for instance A.J. McAuley 7].

4.6 Implications for the Omicron VOC

Alpha and Omicron each have the Y501-H681 combination which is present in 1,085,434 entries out of the 4.2 million we have examined in this study (i.e. over 25%); this contrasts with the Y501-R681 of which we have only found 3,688 observations. Just as the Q.4 sub-lineage with Y501-R681emerged when the Alpha VOC started to spread, it is possible that a new sub-lineage of Omicron with Y501-R681 could emerge given the rapid rise of this latest VOC [N. Ferguson 32, S. Cele 33, J.R.C. Pulliam 34]. The spread of VOC in immunocompromised patients could lead to mutations with a selective advantage for antibody escape and/or transmissibility (e.g. N501Y and P681H/R), in addition to a

number of deletions in the N terminal domain [L. Corey 35], and this aspect needs further investigation given Omicron's large number of mutations (many of them yet to be studied in depth). The adaptation and evolution of this virus in new hosts, for instance mice and rats, also pose additional risks such as additional reservoirs and reinfection of humans [M.J. Kuiper 11]. Investigations into the dynamics affecting the SARS-CoV-2 pandemic in each of the eight countries are also warranted, in the wider context of travel restrictions, population demographics and dynamics [K.A. Grépin 36, J. Liebig 37]. Lack of patient-deidentified metadata in a consistent format further complicates meaningful analysis as emphasized before [D.C. Bauer 16].

4.7 SARS-CoV-2 evolution and selective pressures on quasispecies

Any virus which is new to a host will undergo a period of adaptation, as numerous selective pressures come to bear. RNA viruses, such as coronaviruses, are error-prone in their replication and exist as a cloud of variants, with the dominant clade representing the majority population, but with a number of diverse variants also represented within the population, known as quasispecies [D.C. Bauer 2, C.O. Wilke 3, E. Domingo 38, T.W. Drew 39]. Among viruses which are established in their host, the dominant clade is generally relatively 'fit' in its ability to replicate and out-competes all the other clades. However, when a virus is new to a host, its relative fitness may be quite low, so, in any particular environment, different clades can have similar relative fitness. This means subtle differences might give a particular clade a small advantage enabling it to predominate as the population continues its host adaptation. The environment may comprise of host factors, such as host genetics, tissue tropism, age, immune status or competence, presence of other infections, as well as external factors, such as temperature and humidity. With SARS-CoV-2, the extraordinary public health measures in some regions of the world are likely exerting their own selective pressures on its evolution and creating numerous local environments. This phenomenon, called the 'survival of the flattest' [C.O. Wilke 3] can lead to the emergence of multiple clades dominating under different environments. These is also an increasing appreciation that, within the host, different clades may predominate in different tissues at the same time and that there may be interactions among the diverse quasispecies that facilitate the infection [F. Sun 40].

The pathway of adaptation is not always towards severe disease, since this may not lead to maximum replication and transmission. Indeed, many viruses with a long history of acute infection in an established host species, the disease may be mild or inapparent, reflecting a relationship more towards stasis, where the impact on the host does not compromise the chances of the progeny virus being transmitted to a new host. For many coronaviruses, we have seen an evolution towards milder infection, albeit with greater transmission rates than has been seen with SARS-CoV-2 to date. Certainly, some level of reduction in the efficacy of vaccine-induced antibody in neutralising the Delta and Omicron variants has been demonstrated, but the other feature of these viruses, which is less often discussed, is the ability of these VOC to replicate by means of syncytial formation, rather than the simple apoptotic cycle seen with earlier variants [L. Lin 41]. This may confer an important immune evasive aspect to replication, which might offer a distinct advantage, in immune avoidance. It might also explain why these clades are more productive and less pathogenic since systemic infection is not always involved.

4.8 Error catastrophe, Muller's ratchet and implications for SARS-CoV-2

A phenomenon related to quasispecies evolution is that of error catastrophe, which may occur if the mutational rate exceeds the ability of the fitness landscape to accommodate the resultant evolving clades [H. Tejero 42]. The key triggers for this are not fully understood, but it is thought that the application of strict biosecurity measures may play a part by restricting the availability of new hosts. In such cases, the quasispecies becomes increasingly attenuated, with mutations accumulating via a mechanism called 'Muller's ratchet', to the point where the epidemic may die out [J.G.G. de Alcañíz 43]. This has been seen in many prior outbreaks of Ebola, where the infection became increasingly less pathogenic and less transmissible. While the current environment of SARS-CoV-2 is complex and highly variable, the selective pressure on a virus is towards higher transmissibility and milder disease in all environments, and the current systems of control preferentially select for such. Once a virus develops either/both of these traits, it is very unusual for the reverse to occur because viruses with higher transmissibility out-compete those with lesser transmissibility and those which are milder disable the host less, so they continue to travel and mix with susceptible hosts. It remains to be seen if this is being observed with the Omicron VOC as early reports indicate higher transmissibility and less severe disease.

In comparing variants of SARS-CoV-2, it is tempting to focus on specific mutations and their location – also perhaps with overt attention being paid to the Spike protein, especially its receptor binding domain – and not consider that the observed changes could evolve independently of each other. The secondary and tertiary folding of proteins, as well as post translational modifications, can have a profound effect on function, such that a mutation at one site might require a complimentary change at another site in order to confer advantage, or be wiped out by another, seemingly unrelated change. For the same reason, convergent evolution, might also occur, exhibited by the co-existence of identical co-mutations in virus clades of different lineage [H. Brüssow 44]. Another phenomenon known to occur in many coronaviruses is recombination, where partial genomic exchange may occur between two coronaviruses when simultaneously infecting the same host. The extent to which this may have occurred in SARS-CoV-2 is the likely subject of future analysis [D. Haddad 45, S. Pollet 46].

5. Conclusions and Limitations

SARS-CoV-2 is the most sequenced virus in the world, however, there is an inherent bias introduced by the highly variable sequencing-to-COVID-19 positivity ratio (S:P) across countries (e.g., the UK has one of the highest P:S ratios in the world), and across time (S:P has generally gone up in all countries, e.g. India). Thus, the GISAID data is likely to contain non-random samples with a skew in favour of sequences associated with epidemiologically consequent cases, albeit this is difficult to decipher as most sequences have little or no meaningful patient-deidentified information. The lockdowns and vaccination coverage associated with this viral pandemic have also been unprecedented in human history and spatio-temporally variable, further complicating our analysis. Notwithstanding these limitations, which have led to the proliferation of certain clades in certain environments, we are still able to make broad conclusions thanks to the very large number of sequences available on GISAID. We are also able to demonstrate a process and pipeline to analyse mutations of structural, functional and epidemiological consequence from public domain information in a systematic manner and provide early warnings of certain combinations starting to spread. Though it is unclear which combinations of

mutations provide the best selective advantage, there is concern that mutations previously observed in other dominant lineages may arise spontaneously in contemporary strains further increasing their potential for infectivity and adverse clinical outcomes. In this case-study we analysed three key mutations (viz. D614G, N501Y and P681R) cooccurring but found no evidence of this combination spreading. Although 3,678 sequences were found on GISAID between 17 October 2020 to 1 November 2021, mainly in France, Turkey and USA, the Y501-R681 combination hasn't outcompeted other variants and this warrants further *in silico*, *in vitro* and *in vivo* investigations. With the latest VOC Omicron containing a large number of mutations, many yet to be studied in-depth, our methodology will be very useful to understand whether certain combinations of mutations are more transmissible. If GISAID entries are strengthened with patient-deidentified metadata, then this approach could enable early epidemiological intelligence, for instance on case severity, mortality, and factors such as age, gender, race and co-morbidities that could increase the infection risk.

Acknowledgments

General: We are grateful for support from our CSIRO colleagues at the Australian Centre for Disease Preparedness (https://www.grid.ac/institutes/grid.413322.5), especially Kim Blasdell, Simran Chahal, Alexander McAuley and Nagendrakumar Singanallur, and the Australian e-Health Research Centre, especially Denis Bauer, David Hansen, Yatish Jain, Brendan Hosking and Aidan Tay.

Author contributions: Describe the contributions of each author (use initials) to the paper. Conceptualization and methodology, S.S.V.; bioinformatics, C.L. and L.O.W.W.; biomolecular modelling and interpretation, M.J.K. and T.W.D.; data analysis and original draft preparation, S.M., C.L. and S.S.V.; funding acquisition, S.S.V. and L.O.W.W.; manuscript review and editing, all authors.

Competing interests: None declared.

Data Availability: This paper only uses publicly accessible data that can be downloaded from GISAID, the world's largest repository of SARS-CoV-2 genome sequences. The lists of GISAID's EPI_ISL_ sample IDs and data used by our analysis can be requested from the corresponding author. Our Python code is available at https://github.com/Carol-Lee-gh/Covid-Mutation-Pipieline.git.

Ethics Statement, Identifying Information and Clinical Trial Registration: This study does not involve any human samples, identifiable human data or patient records. It only involves bioinformatics analysis of novel coronavirus genome sequences openly accessible from the public repository 'GISAID', and these sequences do not contain any metadata that can be identified with any individual. This includes sample collection dates and anonymous sample IDs that are openly accessible. Our study does not report any exact age or photographs. Clinical trial registration is not applicable as this is neither an interventional study nor an observational study involving humans.

Funding: This work was supported by funding (Principal Investigator: S.S.V.) from the CSIRO Future Science Platforms, National Health and Medical Research Council (MRF2009092), and United States Food and Drug Administration (FDA) Medical Countermeasures Initiative contract (75F40121C00144); and by funding (Principal

Investigator: L.O.W.W.) from the Australian Academy of Science and the Australian Department of Industry, Science, Energy and Resources. The article reflects the views of the authors and does not represent the views or policies of the funding agencies including the FDA.

References

1. P. Zhou, X.L. Yang, X.G. Wang et al., "A pneumonia outbreak associated with a new coronavirus of probable bat origin," *Nature*, vol. 579, no. 7798, pp. 270-273, 2020, https://doi.org/10.1038/s41586-020-2012-7.

2. D.C. Bauer, A.P. Tay, L.O.W. Wilson et al, "Supporting pandemic response using genomics and bioinformatics: A case study on the emergent SARS-CoV-2 outbreak," *Transboundary and Emerging Diseases*, vol. 67, no. 4, pp. 1453-1462, 2020, https://doi.org/10.1111/tbed.13588.

3. C.O. Wilke, J.L. Wang, C. Ofria, R.E. Lenski and C. Adami, "Evolution of digital organisms at high mutation rates leads to survival of the flattest," *Nature*, vol. 412, no. 6844, pp. 331-333, 2001, https://doi.org/10.1038/35085569.

4. N.D. Grubaugh, M.E. Petrone and E.C. Holmes, "We shouldn't worry when a virus mutates during disease outbreaks," *Nature Microbiology*, vol. 5, no. 4, pp. 529-530, 2020, https://doi.org/10.1038/s41564-020-0690-4.

5. E. Callaway, "The coronavirus is mutating — does it matter?," *Nature*, vol. 585, no. 7824, pp. 174-177, 2020, https://doi.org/10.1038/d41586-020-02544-6.

6. B. Korber, W.M. Fischer, S. Gnanakaran et al., "Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus," *Cell*, vol. 182, no. 4, pp. 812-827.e19, 2020, https://doi.org/10.1016/j.cell.2020.06.043.

7. A.J. McAuley, M.J. Kuiper, P.A. Durr et al., "Experimental and *in silico* evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 Spike protein," *npj Vaccines*, vol. 5, article no. 96, 2020, https://doi.org/10.1038/s41541-020-00246-8.

8. Y. Liu, J. Liu, K.S. Plante et al., "The N501Y Spike substitution enhances SARS-CoV-2 infection and transmission," *Nature*, 2021, https://doi.org/10.1038/s41586-021-04245-0.

9. S.S. Abdool Karim and T. de Oliveira, "New SARS-CoV-2 variants — clinical, public health, and vaccine implications," *New England Journal of Medicine*, vol. 384, no. 19, pp. 1866-1868, 2021, http://doi.org/10.1056/NEJMc2100362.

10. S. Riddell, S. Goldie, A.J. McAuley et al., "Live virus neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 variants following INO-4800 vaccination of ferrets," *Frontiers in Immunology*, vol. 12, article no. 694857, p. 2475, 2021, https://doi.org/10.3389/fimmu.2021.694857.

11. M.J. Kuiper, L.O.W. Wilson, S. Mangalaganesh et al., "But Mouse, you are not alone: On some severe acute respiratory syndrome coronavirus 2 variants infecting mice," *ILAR Journal*, 2021, http://dx.doi.org/10.1093/ilar/ilab031.

12. E. Callaway, "The mutation that helps Delta spread like wildfire," *Nature*, vol. 596, no. 7873, pp. 472-473, 2021, https://doi.org/10.1038/d41586-021-02275-2.

13. Y. Liu, J. Liu, B.A. Johnson et al., "Delta Spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant," *bioRxiv*, 2021, https://doi.org/10.1101/2021.08.12.456173.

14. T.P. Peacock, C.M. Sheppard, J.C. Brown et al., "The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced Spike cleavage by furin," *bioRxiv*, 2021, https://doi.org/10.1101/2021.05.28.446163.

15. S. Elbe and G. Buckland-Merrett, "Data, disease and diplomacy: GISAID's innovative contribution to global health," *Global Challenges*, vol. 1, no. 1, pp. 33-46, 2017, https://doi.org/10.1002/gch2.1018.

16. D.C. Bauer, A. Metke-Jimenez, S. Maurer-Stroh et al., "Interoperable medical data: The missing link for understanding COVID-19," *Transboundary and Emerging Diseases*, vol. 68, no. 4, pp. 1753-1760, 2021, https://doi.org/10.1111/tbed.13892.

17. D. Wrapp, N. Wang, K.S. Corbett et al., "Cryo-EM structure of the 2019-nCoV Spike in the prefusion conformation," *Science*, vol. 367, no. 6483, pp. 1260-1263, 2020, https://doi.org/10.1126/science.abb2507.

18. J.C. Phillips, R. Braun, W. Wang et al., "Scalable molecular dynamics with NAMD," *Journal of Computational Chemistry*, vol. 26, no. 16, pp. 1781-1802, 2005, https://doi.org/10.1002/jcc.20289.

19. W. Humphrey, A. Dalke and K. Schulten, "VMD: visual molecular dynamics," *Journal of Molecular Graphics*, vol. 14, no. 1, pp. 33-38, 1996, https://doi.org/10.1016/0263-7855(96)00018-5.

20. A.G. Remacle, S.A Shiryaev, E.S. Oh et al., "Substrate cleavage analysis of furin and related proprotein convertases. A comparative study," *The Journal of Biological Chemistry*, vol. 283, no. 30, pp. 20897-20906, 2008, doi:10.1074/jbc.M803762200.

21. M. Mahoney, V.C. Damalanka, M. A. Tartell et al., "A Novel Class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial Lung Cells," *bioRxiv*, 2021, https://doi.org/10.1101/2021.05.06.442935.

22. "Demographics | Statista," 2016-2020. Statista. Available at https://www.statista.com/markets/411/topic/446/demographics/ (accessed: 22 December 2021).

23. K.A. Lythgoe, M. Hall, L. Ferretti, M.D Cesare, G.M. Cockett, A. Trebes, M. Andersson, et al., "SARS-CoV-2 within-host diversity and transmission," *Science*, vol. 372, no. 6539, 2021, https://doi.org/10.1126/science.abg0821.

24. A.A. Latif, J.L. Mullen, M. Alkuzweny, G. Tsueng, M. Cano, E. Haag, J. Zhou, M. Zeller, E. Hufbauer, N. Matteson, C. Wu, K.G. Andersen, A.I. Su, K. Gangavarapu, L.D. Hughes, and the Center for Viral Systems Biology. outbreak.info. Available at https://outbreak.info/location-reports?loc=GBR&selected=Delta&selected=Alpha (accessed: 22 December 2021).

25. H. Ritchie, E. Mathieu, L. Rodés-Guirao, C. Appel, C. Giattino, E. Ortiz-Ospina, J. Hasell, B. Macdonald, D. Beltekian and Max Roser, "Coronavirus pandemic (COVID-19)," 2020. OurWorldInData. Available at https://ourworldindata.org/coronavirus (accessed: 22 December 2021).

26. "Timeline of UK Government Coronavirus Lockdowns," 2021. The Institute for Government. Available at https://www.instituteforgovernment.org.uk/charts/uk-government-coronavirus-lockdowns (accessed: 22 December 2021).

27. "Travel restrictions issued by states in response to the coronavirus (COVID-19) pandemic, 2020-2021," 2021. Ballotpedia. Available at https://ballotpedia.org/Travel_restrictions_issued_by_states_in_response_to_the_coronavirus_(COVID-19)_pandemic,_2020-2021 (accessed: 22 December 2021).

28. T.T.N. Thao, F. Labroussaa, N. Ebert, P. V'kovski, H. Stalder, J. Portmann, J. Kelly et al., "Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform," *Nature*, vol. 582, no. 7813, pp. 561-565, 2020, https://doi.org/10.1038/s41586-020-2294-9.

29. X. Xie, A. Muruato, K.G. Lokugamage, K. Narayanan, X. Zhang, J. Zou, J. Liu et al., "An infectious CDNA clone of SARS-CoV-2," *Cell Host Microbe*, vol. 27, no. 5, pp. 841-848, 2020, https://doi.org/10.1016/j.chom.2020.04.004.

30. Y.J. Hou, K. Okuda, C.E. Edwards, D. R. Martinez, T. Asakura, K. H. Dinnon 3rd, T. Kato et al., "SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract," *Cell*, vol. 182, no. 2, pp. 429-446, 2020, https://doi.org/10.1016/j.cell.2020.05.042.

31. X. Xie, K.G. Lokugamage, X. Zhang, M.N. Vu, A.E. Muruato, V.D. Menachery and P.Y Shi, "Engineering SARS-CoV-2 using a reverse genetic system," *Nature Protocols*, vol. 16, no. 3, pp. 1761-1784, 2021, https://doi.org/10.1038/s41596-021-00491-8.

32. N. Ferguson, A. Ghani, A. Cori, A. Hogan, W. Hinsley, and E.Volz. 2021. "Report 49 - Growth, population distribution and immune escape of Omicron in England," *Imperial College London*, Available at https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/ (accessed: 22 December 2021).

33. S. Cele, L. Jackson, D.S. Khoury, K. Khan, T. Moyo-Gwete, H. Tegally, J.E San et al., "SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ace2 for infection," *medRxiv*, 2021, https://doi.org/10.1101/2021.12.08.21267417.

34. J.R.C. Pulliam, C.V Schalkwyk, N. Govender, A.V Gottberg, C. Cohen, M.J. Groome, J. Dushoff, K. Mlisana and H. Moultrie, "Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa," *medRxiv*, 2021, https://doi.org/10.1101/2021.11.11.21266068.

35. L. Corey, C. Beyrer, M.S. Cohen, N.L. Michael, T. Bedford and M. Rolland, "SARS-CoV-2 variants in patients with immunosuppression," *New England Journal of Medicine*, vol. 385, no. 6, pp. 562-566, 2021, https://doi.org/10.1056/NEJMsb2104756.

36. K.A. Grépin, T.L Ho, Z. Liu, S. Marion, J. Piper, C.Z. Worsnop and K. Lee, "Evidence of the effectiveness of travel-related measures during the early phase of the COVID-19 pandemic: A rapid systematic review," *BMJ Global Health*, vol. 6, no. 3, 2021, https://doi.org/10.1136/bmjgh-2020-004537.

37. J. Liebig, K. Najeebullah, R. Jurdak, A.E Shoghri and D. Paini, "Should international borders re-open? The impact of travel restrictions on COVID-19 importation risk," *BMC Public Health*, vol. 21, no. 1, 2021, https://doi.org/10.1186/s12889-021-11616-9.

38. E. Domingo and C. Perales, "Viral quasispecies," *PLoS Genetics*, vol. 15, no. 10, 2019, https://doi.org/10.1371/journal.pgen.1008271.

39. T.W. Drew, "The emergence and evolution of swine viral diseases: To what extent have husbandry systems and global trade contributed to their distribution and diversity," *Revue Scientifique et Technique de l'OIE*, vol. 30, no. 1, pp. 95-106, 2011, https://doi.org/10.20506/rst.30.1.2020.

40. F. Sun, X. Wang, S. Tan, Y. Dan, Y. Lu, J. Zhang, J. Xu et al., "SARS-CoV-2 quasispecies provides an advantage mutation pool for the epidemic variants," *Microbiology Spectrum*, vol. 9, no. 1, 2021, https://doi.org/10.1128/Spectrum.00261-21.

41. L. Li, Q. Li and Y. Shi, "Syncytia formation during SARS-CoV-2 lung infection: a disastrous unity to eliminate lymphocytes," *Cell Death & Differentiation*, vol. 28, 2021, https://doi.org/10.1038/s41418-021-00795-y

42. H. Tejero, A. Marín and F. Montero, "The relationship between the error catastrophe, survival of the flattest, and natural selection," *BMC Evolutionary Biology*, vol. 11, no. 1, 2011, https://doi.org/10.1186/1471-2148-11-2.

43. J.G.G. de Alcañíz, V. López-Rodas and E. Costas, "Sword of Damocles or choosing well. Population genetics sheds light into the future of the COVID-19 pandemic and SARS-CoV-2 new mutant strains." *medRxiv*, 2021, https://doi.org/10.1101/2021.01.16.21249924.

44. H. Brüssow, "COVID-19: emergence and mutational diversification of SARS-CoV-2," *Microbial Biotechnology*, vol. 14, no. 3, pp. 756-768, 2021, https://doi.org/10.1111/1751-7915.13800.

45. D. Haddad, S.E. John, A. Mohammad, M.M. Hammad, P. Hebbar, A. Channanath, R. Nizam, S. Al-Qabandi, A.A. Madhoun, A. Alshukry, H. Ali, T.A. Thanaraj and F. Al-Mulla, "SARS-CoV-2: Possible recombination and emergence of potentially more virulent strains," *PLoS One*, 2021, https://doi.org/10.1371/journal.pone.0251368.

46. S. Pollett, M.A. Conte, M. Sanborn, R.G. Jarman, G.M. Lidl, K. Modjarrad and I.M. Berry, "A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic," *Scientific Reports*, vol. 11, article no. 17365, 2021, https://doi.org/10.1038/s41598-021-96626-8.

Figures– five of them Figures 1-5



Figure 1. Summary of SARS-CoV-2 lineages and sub-lineages containing the D614G, N501Y and P681R mutations of current interest (MOCI) on GISAID. 3,678 sequences were found with our MOCI from a total of 4,177,098. Bold numbers in each box shows the number of observations for each VOC/VOI and their sub-lineages (where such information was available). 'Others' indicate samples not further classified on GISAID.



Figure 2: Discrete timeline depicting the start and end dates (visual approximations) during which SARS-CoV-2 variants with the P681R, N501Y and D614G mutations were observed in various countries, states and cities between October 2020 and October 2021. Countries with 50 or more observations, and states/cities with 10 or more observations are deemed significant and thus included in this timeline. Raw data with the full list of countries are provided in Supplementary **Table S2.**



Figure 3. Continuous representation of the timeline during which SARS-CoV-2 variants with the P681R/H, N501Y and D614G mutations were observed between October 2020 and October 2021. (A) Number of isolates with MOCI, plotted as 14-day rolling average, in the eight countries which had at least 50 observations. The vertical red line shows the first recorded cooccurrence in Slovenia on 17 October 2020; **(B-D)** Number of VOC sequences observed in the top three countries (France, Turkey, USA respectively); **(E-F)** Number of isolates with MOCI which are also VOC, plotted as 14-day rolling average, either from the notional start of the pandemic in December 2019, or from September, May, November and October 2020 as the first reported months for Alpha, Beta, Gamma and Delta respectively. **(G-H)** Number of isolates with the P681H (rather than P681R), N501Y and D614G, plotted as 14-day rolling average, either from the notional start of the pandemic in December 2019, or from the month of first report for each VOC. 'Other' indicates MOCI found in variants other than these VOC.



Figure 4. Model of the SARS-CoV-2 Spike trimer protein indicating the relative position of the P681R, N501Y and D614G mutations of current interest (MOCI). The N501Y mutation occurs in the receptor binding domain (highlighted in cyan) and is associated with increased binding affinity to the ACE2 receptor (shown in yellow). The P681R mutation is implicated with more efficient cleavage of the S1/S2 furin site (required prior to viral fusion to the host cell). Mutation D614G occurs at the S1/S2 interface and has also been implicated with increased replication efficiency.



Figure 5. World map depicting the 65 countries where SARS-CoV-2 variants containing the co-occurring MOCI were recorded between October 2020 and October 2021 (A). A zoomed in view of the regions observed with MOCI are shown for **(B)** Sweden **(C)** Denmark and **(D)** USA. Countries are color-coded based on the number of records of MOCI observed, as shown in the legend, greyed out regions indicate no observations. For some countries such as Turkey, region information was not available, but EPI numbers can be provided upon request.

Supplementary Figures – two of them S1 and S2



Supplementary Figure S1. Frequency of the P681R, N501Y and D614G mutations cooccurring in countries with more than 50 observations between October 2020 and October 2021. For visual clarity, only the SARS-CoV-2 lineage with the maximum count is labelled.



Supplementary Figure S2. Rolling average (14-days) of the P681R, N501Y and D614G mutations cooccurring in Beta, Gamma and Delta VOC. (A) Number of isolates with MOCI from the notional start of the pandemic in December 2019, or **(B)** From May, November and October 2020 as the first reported months for Beta, Gamma and Delta respectively. 'Other' indicates the combination of mutations occurring in variants other than these VOC.

Supplementary Tables – four of them S1, S2, S3 and S4

Supplementary Table S1. GISAID data on key SARS-CoV-2 mutations classified by VOC/VOI. Live analysis from EpiCoV (as of 3 November 2021) containing the results for each of our MOCI, and counts for VOC/VOI according to GISAID. This is compared with data downloaded from GISAID (as of 1 November 2021) and analysed using our in-house alignment pipeline (*complete human-origin genomes) after filtering for correct dates in the metadata ('YYYY-MM-DD').

	GISAID live analysis using EpiCoV	Data downloaded from GISAID	Data downloaded from GISAID (correct dates)
Total	4,835,087	4,766,139	
Human origin	4,831,865	4,763,023	
Human and complete	4,748,462	*4,294,469	4,177,098
D614G	4,692,072	4,245,283	4,129,785
N501Y	1,282,756	1,255,861	1,220,340
P681R	2,288,985	1,887,719	1,844,450
Alpha	1,135,705	1,127,758	1,096,665
Beta	38,865	39,478	37,935
Gamma	113,091	96,217	92,164
Delta	2,267,806	1,871,122	1,828,769
Lambda	8,771	8,149	8,084
Mu	13,042	12,447	11,814

Supplementary Table S2. Raw data for countries with cooccurring P681R, N501Y and D614G mutations. Frequencies for each region and continent are provided as sub-totals and totals respectively.

Continent	Region	Country	Frequency	Sub-totals	Totals
Africa	Eastern Africa	Reunion	2	2	15
Africa	Sub-Saharan Africa	Botswana	2	13	
Africa	Sub-Saharan Africa	Malawi	2		
Africa	Sub-Saharan Africa	Mozambique	1		
Africa	Sub-Saharan Africa	Republic of the Congo	1		
Africa	Sub-Saharan Africa	South Africa	7		
Americas	Latin America and the Caribbean	Argentina	1	259	1078
Americas	Latin America and the Caribbean	Brazil	214		
Americas	Latin America and the Caribbean	Chile	2		
Americas	Latin America and the Caribbean	Colombia	1		
Americas	Latin America and the Caribbean	Czech Republic	23		
Americas	Latin America and the Caribbean	Ecuador	5		
Americas	Latin America and the Caribbean	Martinique	4		
Americas	Latin America and the Caribbean	Mexico	5		
Americas	Latin America and the Caribbean	Puerto Rico	4		
Americas	Northern America	Canada	5	819	
Americas	Northern America	USA	814		
Asia	Central Asia	Uzbekistan	1	1	856
Asia	Eastern Asia	Japan	4	5	
Asia	Eastern Asia	South Korea	1	11	
Asia	South-eastern Asia	Cambodia	2		
Asia	South-eastern Asia	Malaysia	1		
Asia	South-eastern Asia	Philippines	4		
Asia	South-eastern Asia	Singapore	3		
Asia	South-eastern Asia	Thailand	1		
Asia	Southern Asia	Bangladesh	5	28	
Asia	Southern Asia	India	21		
Asia	Southern Asia	Pakistan	1		
Asia	Southern Asia	Sri Lanka	1		
Asia	Western Asia	Georgia	3	811	
Asia	Western Asia	Iraq	1		

Asia	Western Asia	Israel	18		
Asia	Western Asia	Turkey	786		
Asia	Western Asia	United Arab Emirates	3		
Europe	Eastern Europe	Bulgaria	2	73	1728
Europe	Eastern Europe	Hungary	2		
Europe	Eastern Europe	Poland	12		
Europe	Eastern Europe	Romania	10		
Europe	Eastern Europe	Slovakia	45		
Europe	Eastern Europe	Ukraine	2		
Europe	Northern Europe	Denmark	69	472	
Europe	Northern Europe	Estonia	26		
Europe	Northern Europe	Finland	2		
Europe	Northern Europe	Iceland	8		
Europe	Northern Europe	Ireland	38		
Europe	Northern Europe	Latvia	1		
Europe	Northern Europe	Lithuania	2		
Europe	Northern Europe	Norway	2		
Europe	Northern Europe	Sweden	191		
Europe	Northern Europe	United Kingdom	133		
Europe	Southern Europe	Croatia	12	117	
Europe	Southern Europe	Greece	7		
Europe	Southern Europe	Italy	47		
Europe	Southern Europe	Malta	1		
Europe	Southern Europe	Portugal	28		
Europe	Southern Europe	Slovenia	1		
Europe	Southern Europe	Spain	21		
Europe	Western Europe	Austria	8	1066	
Europe	Western Europe	Belgium	21		
Europe	Western Europe	France	836		
Europe	Western Europe	Germany	133		
Europe	Western Europe	Luxembourg	8		
Europe	Western Europe	Netherlands	22		
Europe	Western Europe	Switzerland	38		
Oceania	Australia and New Zealand	New Zealand	1	1	1

Supplementary Table S3. Observation of key mutations and their combinations on GISAID. Live analysis from EpiCoV (as of 3 November 2021) containing the results for each of our MOCI, and counts for VOC/VOI according to GISAID. This is compared with data downloaded from GISAID (as of 1 November 2021) and analysed using our in-house alignment pipeline (*complete human-origin genomes) after filtering for correct dates in the metadata ('YYYY-MM-DD').

	GISAID live analysis using EpiCoV	**Data downloaded from GISAID (correct dates)**
D614G	4,245,283	4,129,785
N501Y	1,255,861	1,220,340
P681R	1,887,719	1,844,450
D614G + N501Y	1,251,360	1,216,080
D614G + P681R	1,882,323	1,839,455
N501Y + P681R	3,728	3,688
D614G + N501Y + P681R	3,718	3,678
D614G + N501Y + P681H	1,112,530	1,082,482
Alpha	1,127,758	1,096,665
Beta	39,478	37,935
Gamma	96,217	92,164
Delta	1,871,122	1,828,769
Alpha + P681R	2,393	2,352[a]
Beta + P681R	24	24[b]
Gamma + P681R	294	294[c]
Delta + N501Y	917	912[d]

[a] mostly present in the sub-lineage Q.4 (2119 samples, since 13 December 2020), B.1.1.7 (230 samples, 17 October 2020)
[b] mostly present in B.1.351 (23 samples, since 30 March 2021)
[c] mostly present in sub-lineage P.1.8 (180 samples, since 20 August 2021)
[d] mostly present in B.1.617.2 (476 samples, since 29 March 2021), sub-lineage AY.33 (155 samples, since 30 April 2021)

Supplementary Table S4. Obversation of other key SARS-CoV-2 Spike mutations. Live analysis from EpiCoV (as of 3 November 2021) containing the results for other key Spike mutations according to GISAID. This is compared with data downloaded from GISAID (as of 1 November 2021) and analysed using our in-house alignment pipeline (*complete human-origin genomes) after filtering for correct dates in the metadata ('YYYY-MM-DD').

	GISAID live analysis using EpiCoV	**Data downloaded from GISAID**	**Data downloaded from GISAID (correct dates)**
Total	4,835,087	4,766,139	
Human	4,831,865	4,763,023	
Human complete	4,748,462	4,294,469*	4,177,098
L18F	212,488	197,955	191,238
T20N	108,445	93,507	89,541
H69del	1,123,439	1,138,302	1,108,661
Y145del	1,364	2,617	2,563
A222V	403,457	367,047	352,024
K417N	44,282	43,114	41,449
N439K	35,253	35,135	34,365
L452R	2,304,322	1,919,808	1,877,945
Y453F	1,255	1,242	1,221
G476S	933	799	764
S477N	70,642	69,479	67,649
T478I	902	892	879
V483A	296	264	243
E484K	225,663	205,807	197,301
E484Q	11,834	10,746	9,998
E780Q	5,931	5,733	5,627
V1176F	125,546	108,949	103,509



VOI	Former VOI	Former VOI	Others
Mu (B.1.621)	Kappa (B.1.617.1)	Iota (B.1.596)	
12	*8*	*1*	*373*


High risk locations (>100 entries)
Medium risk locations (20-100 entries)
Low risk locations (<20 entries)
Country
State
City
COUNTRY
STATE
CITY
Oct '20
Nov '20
Dec '20
Jan '21
Feb '21
Mar '21
Apr '21
May '21
Jun '21
Jul '21
Aug '21
Sep '21
Oct '21
Entries
Brazil 214
Rio de Janeiro 100
Rio de Janeiro 22
Santa Catarina 34
Sao Paulo 51
Denmark 69
Hovedstaden 48
France 836
Auvergne-Rhone-Alpes 76
Lyon 41
Bretagne 27
Centre Val de Loire 11
Grand Est 15
Hauts-de-France 15
Ile-de-France 318
Levallois Perret 12
Paris 52
Normandie 26
Nouvelle-Aquitaine 115
Bordeaux 31
Limoges 16
Perigueux 14
Saint-Astier 11
Occitanie 71
Haute-Garonne 44
Pays de la Loire 21
Provence-Alpes-Cote d'Azur 106
Marseille 92
Germany 133
Bavaria 13
North Rhine-Westphalia 12
Saarland 63
Saxony 11
Sweden 191
Sormland 96
Stockholm 19
Uppsala 26
Vastmanland 33
Turkey 786
United Kindgom 133
England 117
USA 814
California 12
Colorado 13
Connecticut 24
Florida 24
Maryland 74
Massachusetts 427
New Hampshire 28
New York 35
New York City 21
Pennsylvania 20
Rhode Island 34
Texas 15
Virginia 13
West Virginia 12


(A)
Brazil
France
Denmark
Germany
Sweden
Turkey
United Kingdom
USA
Number of MOCI (14-days)
Date
(B)
France
Alpha
Beta
Gamma
Delta
Number of sequences
(C)
Turkey
Alpha
Beta
Gamma
Delta
Number of sequences
(D)
USA
Alpha
Beta
Gamma
Delta
Number of sequences
Date
(F)
Alpha
Beta
Gamma
Delta
Other
Rolling average (14-days)
Days
(G)
Alpha
Beta
Gamma
Delta
Other
Rolling average (14-days)
(H)
Alpha
Beta
Gamma
Delta
Rolling average (14-days)
Days


ACE2 receptor
N501Y
receptor binding domain
S1 domain
D614G
P681R
furin
cleavage site
S2 domains


(A)
Records
836
418
1
(B)
Sweden
Records
100
50
1
Darlana
Uppsala
Stockholm
Västmanland
Södermanland
Östergötland
(C)
Denmark
Records
48
24
1
Nordjylland
Midtylland
Hovedstaden
Syddanmark
Sjælland
(D)
USA
New Hamshire
Michigan
Massachusetts
Rhode Is.
Connecticut
New Jersey
Delaware
Maryland
Florida
Washington
Oregon
California
Nevada
Arizona
Wyoming
Colorado
New Mexico
Texas
North Dakota
Minnesota
Wisconsin
Iowa
Kansas
Missouri
Arkansas
Louisiana
Illinois
Ohio
Pennsylvania
New York
Maine
W. Virginia
Virginia
N. Carolina
S. Carolina
Georgia
Alabama
Records
427
214
1